- Home
- CMBM vs CELU Comparison
CMBM vs CELU Comparison
Compare CMBM & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | CELU |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 56.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMBM | CELU |
|---|---|---|
| Price | $1.60 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 7.8M | 66.9K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,215,000.00 | $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $1.00 |
| 52 Week High | $6.80 | $4.35 |
Technical Indicators
Market Signals| Indicator | CMBM | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 57.19 |
| Support Level | $1.55 | $1.62 |
| Resistance Level | $2.13 | $2.18 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 2.29 | 63.58 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.